Adverum Biotechnologies (NasdaqGM:ADVM) - Share price, News & Analysis

ADVM fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

ADVM Stock Overview

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases.

Risk Analysis

Earnings are forecast to decline by an average of 0.2% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($82M)

Adverum Biotechnologies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Adverum Biotechnologies
Historical stock prices
Current Share Price	US$0.85
52 Week High	US$3.86
52 Week Low	US$0.80
Beta	1.28
1 Month Change	-23.72%
3 Month Change	-37.64%
1 Year Change	-75.73%
3 Year Change	-90.68%
5 Year Change	-67.76%
Change since IPO	-96.60%

Recent News & Updates

May 12

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

	ADVM	US Biotechs	US Market
7D	-6.0%	3.6%	0.1%
1Y	-75.7%	-22.1%	-12.7%

Return vs Industry: ADVM underperformed the US Biotechs industry which returned -21.4% over the past year.

Return vs Market: ADVM underperformed the US Market which returned -11.5% over the past year.

Price Volatility

Is ADVM's price volatile compared to industry and market?
ADVM volatility
ADVM Average Weekly Movement	8.5%
Biotechs Industry Average Movement	12.4%
Market Average Movement	8.0%
10% most volatile stocks in US Market	17.0%
10% least volatile stocks in US Market	3.0%

Stable Share Price: ADVM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ADVM's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2006	188	Laurent Fischer	https://www.adverum.com

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek.

Adverum Biotechnologies Fundamentals Summary

How do Adverum Biotechnologies's earnings and revenue compare to its market cap?
ADVM fundamental statistics
Market Cap	US$82.31m
Earnings (TTM)	-US$155.01m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Is ADVM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADVM income statement (TTM)
Revenue	US$0
Cost of Revenue	US$88.78m
Gross Profit	-US$88.77m
Other Expenses	US$66.24m
Earnings	-US$155.01m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-1.57
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ADVM perform over the long term?

See historical performance and comparison

Valuation

Is Adverum Biotechnologies undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

0.3x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ADVM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ADVM's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: ADVM is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ADVM is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ADVM's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ADVM is good value based on its PB Ratio (0.3x) compared to the US Biotechs industry average (1.5x).

Future Growth

How is Adverum Biotechnologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-0.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADVM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ADVM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ADVM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ADVM is forecast to have no revenue next year.

High Growth Revenue: ADVM is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ADVM's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Adverum Biotechnologies performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-18.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ADVM is currently unprofitable.

Growing Profit Margin: ADVM is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ADVM is unprofitable, and losses have increased over the past 5 years at a rate of 18.3% per year.

Accelerating Growth: Unable to compare ADVM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADVM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: ADVM has a negative Return on Equity (-54.78%), as it is currently unprofitable.

Financial Health

How is Adverum Biotechnologies's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ADVM's short term assets ($280.1M) exceed its short term liabilities ($23.2M).

Long Term Liabilities: ADVM's short term assets ($280.1M) exceed its long term liabilities ($101.2M).

Debt to Equity History and Analysis

Debt Level: ADVM is debt free.

Reducing Debt: ADVM has no debt compared to 5 years ago when its debt to equity ratio was 0.04%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ADVM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ADVM has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 21.7% each year.

Dividend

What is Adverum Biotechnologies's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ADVM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ADVM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ADVM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ADVM's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ADVM has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure

CEO

Laurent Fischer (57 yo)

1.92yrs

Tenure

US$8,996,489

Compensation

Dr. Laurent Fischer, M.D., is a Senior Advisor of Frazier Management, L.L.C. since March 2017. He joined the firm in March 2017. He is on the Frazier Life Sciences team and has several years of drug develo...

CEO Compensation Analysis

Compensation vs Market: Laurent's total compensation ($USD9.00M) is above average for companies of similar size in the US market ($USD770.27K).

Compensation vs Earnings: Laurent's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: ADVM's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

Experienced Board: ADVM's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: ADVM insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/19 00:00
End of Day Share Price	2022/05/19 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31